GlassScriptPhysician profile
Barbara M Buttin
NPI 1700876307
$5,158.95
in general payments reported to CMS, 2019-2025
12 companies · $200 in 2025
The $200 reported for 2025 was less than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,296 · 2021: $291 · 2022: $128 · 2023: $2,897 · 2024: $347 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,610 · Food and Beverage: $823 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,610.00 |
| Food and Beverage | $822.91 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immunogen, INC. | $2,788.85 | 2023 | Elahere |
| Intuitive Surgical, INC. | $1,296.12 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $545.81 | 2021-2025 | Lynparza |
| Glaxosmithkline, LLC. | $114.49 | 2024-2025 | Zejula, Jemperli |
| Novartis Pharmaceuticals Corporation | $101.12 | 2023-2024 | |
| Eisai INC. | $98.12 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $95.60 | 2022-2025 | Lynparza, Keytruda, Lenvima |
| Abbvie INC. | $34.62 | 2024-2025 | |
| Myriad Genetic Laboratories, INC. | $25.45 | 2024 | Myrisk |
| Daiichi Sankyo INC. | $23.41 | 2024 | Enhertu |
| Amgen INC. | $21.89 | 2022 | |
| Pfizer INC. | $13.47 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Buttin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.